AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

ACADIA Pharmaceuticals In... (ACAD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

20.36

0.69 (3.51%)

At close: Feb 20, 2025, 3:59 PM

20.29

-0.37%

After-hours: Feb 20, 2025, 04:36 PM EST

undefined% (undefined)

Bid	19.73
Market Cap	3.39B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.78
PE Ratio (ttm)	26.11
Forward PE	n/a
Analyst	Buy

Ask	20.45
Volume	1,167,498
Avg. Volume (20D)	2,493,876
Open	19.62
Previous Close	19.67
Day's Range	19.63 - 20.43
52-Week Range	14.15 - 26.56
Beta	undefined

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psych...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 27, 2004

Employees 620

Stock Exchange NASDAQ

Ticker Symbol ACAD

Website https://www.acadia-pharm.com

Full Company Profile

Analyst Forecast

According to 19 analyst ratings, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 12.94% from the latest price.

Buy 57.89%

Hold 36.84%

Sell 0.00%

Stock Forecasts

Next Earnings Release

ACADIA Pharmaceuticals Inc. is scheduled to release its earnings on Feb 26, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+8.93%

ACADIA Pharmaceuticals shares are trading higher t... Unlock content with Pro Subscription

5 months ago

-2.76%

ACADIA Pharmaceuticals shares are trading lower after the company appointed Catherine Owen Adams as CEO.

News

1 week ago · businesswire.com

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on February 6, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted ind...

1 week ago · zacks.com

Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?

Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.

1 week ago · businesswire.com

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after th...

1 month ago · zacks.com

ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)

Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.

1 month ago · zacks.com

ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals

Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.

1 month ago · businesswire.com

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discu...

1 month ago · zacks.com

Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2 months ago · businesswire.com

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Ad...

2 months ago · businesswire.com

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees ...

2 months ago · businesswire.com

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead...

Load More News